News tagged with pharmaceuticals inc
KaloBios Pharma edges higher following IPO
(AP)—Shares of respiratory drug maker KaloBios Pharmaceuticals are inching higher on the first day of trading.
Other
Feb 01, 2013 |
not rated yet |
0
Drug companies forge partnerships with top schools
(AP)—Pharmaceutical companies that can no longer rely on lucrative patents to drive profits are increasingly teaming up with academia in search of the next big drug discovery.
Medications
Jan 10, 2013 |
3 / 5 (1) |
0
Cervical cancer vaccine shows promise
A vaccine against cervical cancer, being developed by Inovio Pharmaceuticals Inc. of Blue Bell, Pa., produced positive results in a small sample of 18 women.
Cancer
Oct 12, 2012 |
5 / 5 (3) |
0
First generic versions of singulair approved
(HealthDay) -- The first generic versions of Singulair (montelukast sodium) have been approved by the U.S. Food and Drug Administration.
Medications
Aug 04, 2012 |
not rated yet |
0
Higher risk of VTE in CKD surgical patients on enoxaparin
(HealthDay) -- For patients with chronic kidney disease (CKD) who undergo total hip replacement (THR), the rate of major venous thromboembolism (VTE) is significantly higher in those treated with enoxaparin ...
Diseases, Conditions, Syndromes
Jun 08, 2012 |
not rated yet |
0
Alzheimer's drug sharply criticized by medical experts
Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. But a new pill formulated by a respected pharmaceutical company and approved by the Food ...
Alzheimer's disease & dementia
Mar 23, 2012 |
5 / 5 (1) |
0
Drug approved to treat cystic fibrosis' root cause
The first drug that treats the root cause of cystic fibrosis won approval Tuesday, offering a life-changing treatment for a handful of patients with the deadly illness and broader hope for thousands more patients with the ...
Medications
Jan 31, 2012 |
5 / 5 (1) |
0
Novel treatment for skin lymphoma
Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer ...
Cancer
Jan 17, 2012 |
5 / 5 (1) |
0
Bristol-Myers Squibb to buy Inhibitex for $2.5 billion
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).
Medications
Jan 08, 2012 |
not rated yet |
0
